# Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC

> **NCT00283244** · PHASE2 · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 147 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** erlotinib hydrochloride
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00283244
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2014-09
- **Final completion:** 2014-10
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2017-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00283244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00283244, "Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00283244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*